Patent · US Active

Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles

US11730823B2 · kind B2 · utility

4Cited by
39References
28Claims
0Family size

Assignee

Inventor

Key dates

Filing dateOct 3, 2017
Grant dateAug 22, 2023
Priority date—
Expiry dateDec 23, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2795/18122
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods, systems, compositions and strategies for the delivery of RNA into cells in vivo, ex vivo, or in vitro via ARMMs are provided. In some aspects, ARMMs containing fusion proteins of ARRDC1 fused to an RNA binding protein or an RNA binding protein fused to a WW domain are provided. In some aspects, ARMMs containing binding RNAs associated with cargo RNAs are provided. In other aspects, cargo RNAs associated with a binding RNA, such as a TAR element, are loaded into ARMMs via ARRDC1 fusion proteins containing an RNA binding protein, such as trans-activator of transcription (Tat) protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.